Search Results

• • 14 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• A comprehensive review of pacritinib in myelofibrosis

  Authors:Srdan Verstovsek and Rami S KomrokjiFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20157,450 words Report 2070LAuthor(s): Srdan Verstovsek [*] aff1 , Rami S Komrokji aff2 KEYWORDS efficacy; FLT3; JAK2; myelofibrosis; pacritinib; safety; tyrosine kinase inhibitor Epidemiology & pathobiology of myelofibrosis...

• Current biomarkers for diagnosing of prostate cancer

  Authors:Carsten Stephan, Klaus Jung, and Bernhard RallaFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 201510,191 words Report 2020LAuthor(s): Carsten Stephan [*] aff1 aff2 , Klaus Jung aff1 aff2 , Bernhard Ralla aff1 KEYWORDS AUC; cancer; ETS ; free PSA; kallikreins; PCA3 ; phi; prostate; prostate biopsy; prostate volume; PSA; PSA...

• How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?

  Authors:Bekir Hacioglu, Serkan Akin, Taner Babacan, Ali R Sever, and Kadri AltundagFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20151,439 words Report 1620LAuthor(s): Bekir Hacioglu aff1 , Serkan Akin aff1 , Taner Babacan aff1 , Ali R Sever aff2 , Kadri Altundag [*] aff1 KEYWORDS breast; cancer; complete remission; HER2 positive; long term; maintenance therapy;...

• The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment

  Authors:Guy Jerusalem, Marie Moonen, Pierre Freres, and Patrizio LancellottiFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20152,327 words Article 1570LAuthor(s): Guy Jerusalem [*] aff1 , Marie Moonen aff2 , Pierre Freres aff1 , Patrizio Lancellotti aff2 KEYWORDS anthracyclines; breast cancer; cardiac toxicity; cardio-oncology; monitoring; trastuzumab The...

• Robot-assisted radical prostatectomy in prostate cancer

  Authors:Giorgio Gandaglia, Francesco Montorsi, Pierre I Karakiewicz, and Maxine SunFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20155,012 words Report 2040LAuthor(s): Giorgio Gandaglia [*] aff1 aff2 , Francesco Montorsi aff1 , Pierre I Karakiewicz aff2 , Maxine Sun aff2 KEYWORDS biochemical recurrence; cancer-specific survival; erectile dysfunction; healthcare...

• Contemporary approaches to prostate cancer management

  Authors:Jack A Schalken and Gemma WestcottFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 2015964 words Report 1480LAuthor(s): Jack A Schalken [*] aff1 , Gemma Westcott aff2 KEYWORDS biomarkers; early diagnosis; emerging agents; multiparametric MRI; PARP; prostate cancer The early diagnosis of prostate cancer and the...

• Harnessing novel modalities: field carcinogenesis detection for personalizing prostate cancer management

  Authors:Navneet Momi, Vadim Backman, Charles B Brendler, and Hemant K RoyFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20152,403 words Report 1980LAuthor(s): Navneet Momi aff1 , Vadim Backman aff2 , Charles B Brendler aff3 , Hemant K Roy [*] aff1 KEYWORDS biomarker; miRNAs; nanocytology; overdiagnosis; prostate cancer; PWS Prostate cancer Despite being...

• Bortezomib in the treatment of mantle cell lymphoma.

  Author:Tadeusz RobakFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20159,336 words Report 1580LMantle cell lymphoma (MCL) is a hematological malignancy with unfavorable prognosis. Bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, was shown to be active in MCL and is currently...

• Personalized medicine in cancer: where are we today?

  Author:Arran K TurnbullFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20152,765 words Editorial 1670LAuthor(s): Arran K Turnbull [*] aff1 KEYWORDS breast cancer; cancer; personalized medicine What is personalized medicine? In an ideal world, our vision for personalized medicine involves measurement of some key...

• Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis

  Authors:Eduard Vrdoljak, Martin Gore, Sophie Leyman, Cezary Szczylik, Galina Kharkevich, Patrick Schoffski, et al.From:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20155,378 words Report 1740LAuthor(s): Eduard Vrdoljak [*] aff1 , Martin Gore aff2 , Sophie Leyman aff3 , Cezary Szczylik aff4 , Galina Kharkevich aff5 , Patrick Schöffski aff6 , Laszlo Torday aff7 , Josef Mardiak aff8 , Ke Zhang aff9 , Peter...

• .sup.18F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer

  Authors:Ya-Li Cui, Xuemei Wang, and Xiao-Feng LiFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20154,992 words Report 1650LAuthor(s): Ya-Li Cui [*] aff1 , Xuemei Wang aff2 , Xiao-Feng Li [**] aff3 KEYWORDS 18 F-fluoromisonidazole; change in hypoxia; hypoxia; non-small-cell lung cancer; tumor microenvironment Lung cancer is...

• Role of MRI in the diagnosis and management of prostate cancer

  Authors:Andreas G Wibmer, Hebert Alberto Vargas, and Hedvig HricakFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20155,557 words Report 1890LAuthor(s): Andreas G Wibmer [*] aff1 , Hebert Alberto Vargas aff1 , Hedvig Hricak aff1 KEYWORDS cancer detection; cancer recurrence; cancer staging; MRI; prostate cancer; risk assessment; whole-body MRI...

• Corrigendum

  Authors:Colin Watts and Sara GM PiccirilloFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 2015124 words Brief article, Corre... 1260LAuthor(s): Colin Watts [*] aff1 , Sara GM Piccirillo aff2 In the Editorial by Colin Watts, titled 'Clonal diversity in glioblastoma: is it clinically relevant?', which appeared in the June 2015 issue of Future...

• Emerging agents for the therapy of advanced prostate cancer

  Authors:Amanda R Hathaway, Mary Katherine Baker, and Guru SonpavdeFrom:Future Oncology (Vol. 11, Issue 20) Peer-Reviewed

  Oct. 20159,455 words Report 1850LAuthor(s): Amanda R Hathaway aff1 , Mary Katherine Baker aff1 , Guru Sonpavde [*] aff1 KEYWORDS androgen inhibitors; emerging agents; immunotherapy; mCRPC; metastatic castration-resistant prostate cancer...